Baxter International (NYSE:BAX) Releases Q3 2025 Earnings Guidance

Key Points

• Baxter International has updated its Q3 2025 earnings guidance with an expected EPS of 0.580-0.620, lower than the consensus estimate of 0.646, while revenue guidance remains at $2.9 billion.
• The company's stock has seen a significant decline of 18.0%, opening at $23.00 per share, with a current market capitalization of $11.80 billion.
• Baxter recently announced a dividend of $0.17 per share, reflecting an annualized dividend yield of 2.96%, despite a negative payout ratio of -61.82%.

Baxter International (NYSE:BAX - Get Free Report) updated its third quarter 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.580-0.620 for the period, compared to the consensus EPS estimate of 0.646. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $2.9 billion. Baxter International also updated its FY 2025 guidance to 2.420-2.520 EPS.

Analyst Upgrades and Downgrades

Several brokerages have commented on BAX. UBS Group cut their price target on shares of Baxter International from $35.00 to $24.00 and set a "neutral" rating for the company in a report on Monday. Citigroup reduced their price objective on Baxter International from $34.00 to $32.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 9th. Stifel Nicolaus restated a "hold" rating and issued a $25.00 price objective (down previously from $36.00) on shares of Baxter International in a research report on Monday. Wall Street Zen cut shares of Baxter International from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, The Goldman Sachs Group cut shares of Baxter International from a "buy" rating to a "neutral" rating and set a $25.00 price objective on the stock. in a report on Friday. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Baxter International currently has an average rating of "Hold" and a consensus target price of $30.67.

Baxter International Stock Up 2.0%

BAX traded up $0.45 during trading on Monday, hitting $22.41. The stock had a trading volume of 11,386,479 shares, compared to its average volume of 5,060,967. The company has a market capitalization of $11.50 billion, a PE ratio of -74.70, a PEG ratio of 0.71 and a beta of 0.59. Baxter International has a twelve month low of $21.33 and a twelve month high of $40.49. The company has a debt-to-equity ratio of 1.33, a quick ratio of 1.40 and a current ratio of 2.02. The stock has a 50 day simple moving average of $29.52 and a two-hundred day simple moving average of $31.03.

Baxter International (NYSE:BAX - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.01). Baxter International had a positive return on equity of 16.93% and a negative net margin of 1.42%. The business had revenue of $2.81 billion for the quarter, compared to analysts' expectations of $2.82 billion. During the same period last year, the business earned $0.68 EPS. The company's revenue for the quarter was up 4.3% on a year-over-year basis. On average, research analysts predict that Baxter International will post 2.48 earnings per share for the current year.

Baxter International Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 1st. Stockholders of record on Friday, August 29th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Friday, August 29th. This represents a $0.68 annualized dividend and a dividend yield of 3.0%. Baxter International's dividend payout ratio is -226.67%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.